Research ArticleOriginal Article
Open Access

Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome

Relationships to insulin resistance and obesity

Maryam N. Alotibi, Amina M. Alnoury and Amani M. Alhozali
Saudi Medical Journal January 2019, 40 (1) 19-25; DOI: https://doi.org/10.15537/smj.2019.1.22825

References

  1. ↵
    1. Kaur J
    (2014) A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014:943162.
    OpenUrlPubMed
  2. ↵
    1. Ranasinghe P,
    2. Mathangasinghe Y,
    3. Jayawardena R,
    4. Hills A,
    5. Misra A
    (2017) Prevalence and trends of metabolic syndrome among adults in the Asia-Pacific region:a systematic review. BMC Public Health 17:101.
    OpenUrlCrossRef
  3. ↵
    1. Bahijri S,
    2. Al Raddadi R
    (2013) The importance of local criteria in the diagnosis of metabolic syndrome in Saudi Arabia. Ther Adv Endocrinol Metab 4:51–59.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sclafani A
    (2013) Gut–brain nutrient signaling. Appetition vs. satiation. Appetite 71:454–458.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Morton GJ,
    2. Meek TH,
    3. Schwartz MW
    (2014) Neurobiology of food intake in health and disease. Nat Rev Neurosci 15:367–378.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ertuğrul Ö F
    (2018) A novel type of activation function in artificial neural networks:trained activation function. Neural Networks 99:148–157.
    OpenUrl
  7. ↵
    1. Mori M,
    2. Yamada M,
    3. Okada S,
    4. Hashimoto K,
    5. Satoh T,
    6. Shimizu H,
    7. et al.
    (2013) Discovery of nesfatin-1 and overview of biological actions and new developments. Current Pharmaceutical Design 19:6921–6928.
    OpenUrl
  8. ↵
    1. Elran-Barak R,
    2. Accurso E,
    3. Goldschmidt A,
    4. Sztainer M,
    5. Byrne C,
    6. Le Grange D
    (2014) Eating patterns in youth with restricting and binge eating/purging type anorexia nervosa. International Journal of Eating Disorders 47:878–883.
    OpenUrl
  9. ↵
    1. Dore R,
    2. Levata L,
    3. Lehnert H,
    4. Schulz C
    (2017) Nesfatin-1:functions and physiology of a novel regulatory peptide. J Eat Disord 232:R45–R65.
    OpenUrl
  10. ↵
    1. Saldanha JF,
    2. Carrero JJ,
    3. Lobo JC,
    4. Stockler-pinto MB,
    5. Leal VO,
    6. Calixto A,
    7. et al.
    (2012) The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients:are there associations with food intake, body composition and inflammation. Regul Pept 173:82–85.
    OpenUrlPubMed
  11. ↵
    1. Khalili S,
    2. Khaniani S,
    3. Afkhami F,
    4. Derakhshan M
    (2017) NUCB2/=nesfatin-1:a potent meal regulatory hormone and its role in diabetes. Egyptian Journal of Medical Human Genetics 18:105–109.
    OpenUrl
  12. ↵
    1. Nakata M,
    2. Manaka K,
    3. Yamamoto S,
    4. Mori M,
    5. Yada T
    (2011) Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet b-cells. Endocrine Journal 58:305–313.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Ogiso K,
    2. Asakawa A,
    3. Amitani H,
    4. Nakahara T,
    5. Ushikai M,
    6. Haruta I,
    7. et al.
    (2011) Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 32:150–153.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Ramanjaneya M,
    2. Chen J,
    3. Brown J,
    4. Tripathi G,
    5. Hallschmid M,
    6. Patel S,
    7. et al.
    (2010) Identification of nesfatin-1 in human and murine adipose tissue:a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151:3169–3180.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Fang P,
    2. Yu M,
    3. Shi M,
    4. Zhang Z,
    5. Sui Y,
    6. Guo L,
    7. et al.
    (2012) Galanin peptide family as a modulating target for contribution to metabolic syndrome. Gen Comp Endocrinol 179:115–120.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Fang P,
    2. He B,
    3. Shi M,
    4. Kong G,
    5. Dong X,
    6. Zhu Y,
    7. et al.
    (2015) The regulative effect of galanin family members on link of energy metabolism and reproduction. Peptides 71:240–249.
    OpenUrl
  17. ↵
    1. Šípková J,
    2. Kramáriková I,
    3. Hynie S,
    4. Klenerová V
    (2017) The galanin and galanin receptor subtypes, its regulatory role in the biological and pathological functions. Physiol Res 66:729–740.
    OpenUrl
  18. ↵
    1. Fang P,
    2. Shi M,
    3. Zhu Y,
    4. Bo P,
    5. Zhang Z
    (2016) Type 2 diabetes mellitus as a disorder of galanin resistance. Exp Gerontol 73:72–77.
    OpenUrl
    1. Bu L,
    2. Yao Q,
    3. Liu Z,
    4. Tang W,
    5. Zou J,
    6. Qu S
    (2014) Combined galanin with insulin improves insulin sensitivity of diabetic rat muscles. J Endocrinol 221:157–165.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Fang P,
    2. Zhang L,
    3. Yu M,
    4. Sheng Z,
    5. Shi M,
    6. Zhu Y,
    7. et al.
    (2018) Activiated galanin receptor 2 attenuates insulin resistance in skeletal muscle of obese mice. Peptides 99:92–98.
    OpenUrl
  21. ↵
    1. Nergiz S,
    2. Altınkaya S,
    3. Küçük M,
    4. Yüksel H,
    5. Sezer D,
    6. Kurt İ,
    7. et al.
    (2014) Circulating galanin and IL-6 concentrations in gestational diabetes mellitus. Gynecol Endocrinol 30:236–240.
    OpenUrlPubMed
  22. ↵
    1. Alberti K,
    2. Eckel R,
    3. Grundy S,
    4. Zimmer P,
    5. Cleeman J,
    6. Donato K,
    7. et al.
    (2009) Harmonizing the metabolic syndrome:a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and prevention;National Heart, Lung, and Blood Institute;American Heart Association;World Heart Federation;International Atherosclerosis Society;and International Association for the Study of Obesity. Circulation 120:1640–1645.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Celi F,
    2. Bini V,
    3. Papi F,
    4. Santilli E,
    5. Ferretti A,
    6. Mencacci M,
    7. et al.
    (2005) Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes:relationship to insulin therapy, metabolic control and pubertal development. Clinical Endocrinology 63:139–145.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Zhang Z,
    2. Fang P,
    3. Shi M,
    4. Gu C,
    5. Wang Y,
    6. Bo P,
    7. et al.
    (2015) Association between circulating levels of galanin and pre-pregnancy body mass index in patients with gestational diabetes mellitus. Eating Behaviors 19:57–60.
    OpenUrl
  25. ↵
    1. Fang P,
    2. Yu M,
    3. Gu X,
    4. Shi M,
    5. Zhu Y,
    6. Zhang Z,
    7. et al.
    (2017) Low levels of plasma galanin in obese subjects with hypertension. J Endocrinol Invest 40:63–68.
    OpenUrl
  26. ↵
    1. Fang P,
    2. Yu M,
    3. Guo L,
    4. Bo P,
    5. Zhang Z,
    6. Shi M
    (2012) Galanin and its receptors:a novel strategy for appetite control and obesity therapy. Peptides 36:331–339.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Boughton CK,
    2. Murphy KG
    (2013) Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. Br J Pharmacol 170:1333–1348.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Fang P,
    2. Sun J,
    3. Wang X,
    4. Zhang Z,
    5. Bo P,
    6. Shi M
    (2013) Galanin participates in the functional regulation of the diabetic heart. Life Sciences 92:628–632.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Fang P,
    2. Yu M,
    3. Gu X,
    4. Shi M,
    5. Zhu Y,
    6. Zhang Z,
    7. et al.
    (2016) Circulating galanin and galanin like peptide concentrations are correlated with increased triglyceride concentration in obese patients. Clinica Chimica Acta 461:126–129.
    OpenUrl
  30. ↵
    1. Algul S,
    2. Ozkan Y,
    3. Ozcelik O
    (2016) Serum nesfatin-1 levels in patients with different glucose tolerance levels. Physiological Research 65:979–985.
    OpenUrl
  31. ↵
    1. Su Y,
    2. Zhang J,
    3. Tang Y,
    4. Bi F,
    5. Liu Jn
    (2010) The novel function of nesfatin-1:antihyperglycemia. Biochem Biophys Res Commun 391:1039–1042.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Zhai T,
    2. Li S,
    3. Fan X,
    4. Tian Z,
    5. Lu X,
    6. Dong J
    (2017) Circulating nesfatin-1 levels and type 2 diabetes:a systematic review and meta-analysis. J Diabetes Res 2017:1–8.
    OpenUrlPubMed
  33. ↵
    1. Ademoglu En,
    2. Gorar S,
    3. Keskin M,
    4. Carlioglu A,
    5. Ucler R,
    6. Erdamar H,
    7. et al.
    (2017) Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes. Arch Endocrinol Metab 61:455–459.
    OpenUrl
  34. ↵
    1. Deniz R,
    2. Gurates B,
    3. Aydin S,
    4. Celik H,
    5. Sahin İ,
    6. Baykus Y,
    7. et al.
    (2012) Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 42:694–699.
    OpenUrl
  35. ↵
    1. Zhang Z,
    2. Li L,
    3. Yang M,
    4. Liu H,
    5. Boden G,
    6. Yang G
    (2012) Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120:91–95.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Li Z,
    2. Gao L,
    3. Tang H,
    4. Yin Y,
    5. Xiang X,
    6. Li Y,
    7. et al.
    (2013) Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS One 8:e71513.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Anwar G,
    2. Yamamah G,
    3. Ibrahim A,
    4. El-Lebedy D,
    5. Farid T,
    6. Mahmoud R
    (2014) Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regulatory Peptides 188:21–24.
    OpenUrl
  38. ↵
    1. Tan BK,
    2. Hallschmid M,
    3. Kern W,
    4. Lehnert H,
    5. Randeva HS
    (2011) Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans:evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 96:e669–e673.
    OpenUrl
  39. ↵
    1. Basar O,
    2. Akbal E,
    3. Koklu S,
    4. Kocak E,
    5. Tuna Y,
    6. Ekiz F,
    7. et al.
    (2012) A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 72:479–483.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Sahin SB,
    2. Ayaz T,
    3. Cure MC,
    4. Sumer F,
    5. Ilkkilic K
    (2014) Association of nesfatin-1 levels with fasting and postload glucose levels in patients with hypothyroidism. J Exp Clin Med 31:217–220.
    OpenUrl
  41. ↵
    1. Finelli C,
    2. Martelli G,
    3. Rossano R,
    4. Padula MC,
    5. La Sala N,
    6. Sommella L,
    7. Tarantino G
    Nesfatin-1:role as possible new anti-obesity treatment. EXCLI J 2014(13):586–591.
  42. ↵
    1. Osaki A,
    2. Shimizu H
    (2014) Peripheral administration of nesfatin-1 increases blood pressure in mice. Hypertension Research 37:185–186.
    OpenUrl
  43. ↵
    1. Zhao Y,
    2. Ma X,
    3. Wang Q,
    4. Zhou Y,
    5. Zhang Y,
    6. Wu L,
    7. et al.
    (2015) Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population. Clin Exp Hypertens 37:51–56.
    OpenUrl
  44. ↵
    1. Hamedani N.K,
    2. Hosseinzadeh-Attar M.J,
    3. Hosseini M
    (2014) The correlation between nesfatin-1 and blood pressure in healthy normal weight and obese adults. International Research Journal of Applied and Basic Sciences 8:362–364.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section